Here are five notes:
1. An increasing number of surgeries, a growing elderly population with spine diseases and increasing incomes will drive the market’s growth.
2. The spinal fusion market will see new product development and technological advancements.
3. Government initiatives have allowed more Chinese in rural areas to receive spinal treatment.
4. Unfavorable reimbursements, costliness of surgery, risk factors and government regulations will impede the market’s growth.
5. Dominant players in China’s spinal fusion market include Trauson, DePuy Synthes, Biomet, Medtronic, NuVasive, Stryker, Zimmer, Orthofix International, B. Braun Aesculap and Weigao Orthopaedic Device.
More articles on devices:
ConforMIS reports Q4, full year results — 12 things to know
Hip, knee orthopedic surgical implants market to reach $33M by 2022: 3 takeaways
FDA releases new draft guidance for orthopedic device developers — 6 insights
